LUGPA Medlive Virtual Event Series

In collaboration with PlatformQ Health, LUGPA offers members the opportunity to register and participate in a unique educational platform on Medlive. Attendees can take advantage of live streaming panel discussions and debates, along with interactive audience participation, including real-time question and answer sessions with top faculty.

LUGPA Virtual Crossfire and CME Event Series

LUGPA’s Virtual Crossfire Event Series with Medlive is like a live medical conference brought directly to your computer. Participants can choose to submit questions for the expert panel ahead of time or during the live broadcast, allowing presenters to respond in real time, combining benefits of in-person interactive education with the convenience of digital access.

_____________________________________________________________________________

2024 UPCOMING MEDLIVE EVENTS:

October 22 at 12:15pm ET– 2024 Election Insights: Impact on Independent Urology Practices
As the 2024 election approaches, healthcare providers, including urology practices, face a landscape of potential policy changes and regulatory shifts. This 30-minute webinar aims to provide a comprehensive overview of the upcoming election's possible implications for urology practices. Attendees will be able to ask questions and gain valuable insights into how various election outcomes could influence healthcare policies, reimbursement models, regulatory requirements, and overall practice management. Moderator: Evan Goldfischer, MD, MBA, MPH, CPI, President, LUGPA. Panelists: Mara Holton, MD, President, Anne Arundel Urology Chair, LUGPA Health Policy Committee; David Albala, MD, Urologist, Associated Medical Professionals; and Joshua Langston, MD, Chief Medical Officer, Urology of Virginia.

October 28, 2024 at 5:00pm ET
Program Title: The Why and How of Gene Therapy for Patients with High-Risk NMIBC [non-CME]

October 30 at 12:00 PM ET - Advances in Biomarker-directed Therapies in Hormone-sensitive Prostate Cancer: A Focus on the PI3K/AKT Pathway
Part 2: Strategies to Address Community Challenges of Integrating Biomarker-based Management of mHSPC - CME

More Events Coming Soon.

ON DEMAND SESSIONS:

Programs expire six months after their live date.

Finding the Treatments That Work: Entering a New Era in Non-Clear Cell RCC Management - CME On Demand
Live Date: September 23, 2024

A Framework to Manage a New Disease State: High-Risk Biochemically Recurrent Prostate Cancer - non-CME
Live Date: September 18, 2024
Program expiration: March 18, 2025

Advances in Biomarker-directed Therapies in Hormone-sensitive Prostate Cancer: A Focus on the PI3K/AKT Pathway
Part 1: Getting Set for Management of mHSPC with PTEN Loss Utilizing Biomarker-directed Therapies - CME
Live Date: September 10, 2024
Program expiration: March 10, 2024

Imaging Innovation For RCC: Are We There Yet?

Program Type: Crossfire (NON-CME)

Live Date: Wednesday, August 28, 2024

Program learning objectives/program description:

Review the burden of RCC and unmet needs with current diagnostic approaches
Discuss targeted approaches to improve detection of clear cell RCC
Evaluate target-specific PET/CT tracers beyond PSMA (e.g. carbonic anhydrase IX)

Program expiration: Feb. 28, 2024

Taking a Closer Look at High-Risk, Biochemically Recurrent Prostate Cancer

CME Available on-demand: August 5, 2024
Program Faculty: Neal Shore, MD, FACS & Alicia K. Morgans, MD, MPH
Program expiration: Feb. 5, 2024

Real-World Data Guides LG-UTUC Treatment Strategies - originally launched 06/25/2024

Learning Objectives:

Review guideline-based management of low-grade upper tract urothelial carcinoma
Discuss the application of real-world data that can further refine current practice

Speakers: Jason M. Hafron, MD; David Morris, MD, FACS; Rian Dickstein, MD, FACS

Program expiration: 12/25/2024

Refining Treatment Strategies for mHSPC - originally launched May 29, 2024
Neal Shore, MD, FACS moderates a conversation between Gregory C. McMahon, DO and Benjamin Lowentritt, MD, FACS. During this session, our expert panel will discuss the rationale for triplet versus doublet therapies in mHSPC, and they identify how racial and ethnic minorities face disparities in treatment and care. Plus: don't miss out on the audience Q&A!

Program expiration: Nov. 29, 2024

Refining PSMA Testing in Prostate Cancer: Next-Generation Imaging Strategies - launched May 16, 2024 on-demand

Faculty:

Dr. Jason Hafron, Michigan Institute of Urology
Dr. David Schuster, Emory University School of Medicine

CME credit available.

Program expiration: Nov. 16, 2024

EXPIRED PROGRAMS

Practice Matters: Introducing Kidney-Sparing Approaches to UTUC Care
Live Date: 02/26/2024
Program expiration: 08/26/2024

Maintaining Health and Wellbeing in Patients with mHSPC
Live date: January 16, 2024
Program expiration: June 16, 2024

Practical Considerations in Low-grade UTUC Care
Live date: November 28, 2023
Program expiration: May 28, 2024

Optimizing Decision-Making for Patients with mHSPC: Case-Based Review of Doublets and Triplets
Live Date: 10/31/2023
Program Expiration: 3/2/24

Adopting a Kidney-Sparing Approach to UTUC Treatment (NON-CME)
Originally presented 8/31/2023
Program Expiration: 3/2/2024

Moving Beyond ADT Alone: The Rationale for Early Intensification in mHSPC
Originally presented July 12, 2023
Program Expiration: 1/19/2024

Programs expire six months after their live date.